<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196700</url>
  </required_header>
  <id_info>
    <org_study_id>SHARON-H&amp;N</org_study_id>
    <nct_id>NCT03196700</nct_id>
  </id_info>
  <brief_title>Short Course Radiation Therapy in Palliative Treatment</brief_title>
  <official_title>Short Course Accelerated Radiation Therapy in Palliative Treatment of Advanced Head and Neck Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study wants to define the maximum tolerated dose (MTD), safety and efficacy of a short
      course radiation treatment in patients with symptomatic advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study wants to define the maximum tolerated dose (MTD) of a conformal short course
      accelerated radiation therapy delivered in twice daily fractions and 2 consecutive days, and
      the feasibility of this fractionation in term of safety and efficacy for symptomatic
      palliation of metastatic or locally advanced head and neck cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2009</start_date>
  <completion_date type="Actual">June 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
    <description>The maximum tolerated dose is defined as the dose level below the highest administered dose associated with dose limiting toxicity (DLT) in at least one third of patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Acute toxicity after treatment is evaluated with CTCAE scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life after the treatment is evaluated according to CLAS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain relief</measure>
    <time_frame>1 year</time_frame>
    <description>Pain after the therapy is evaluated with the visual analogic scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Late toxicity after the treatment is evaluated with EORTC-RTOG scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Short course radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The radiotherapy is delivered over two days with accelerated hypo-fractionation was delivered</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short course radiotherapy</intervention_name>
    <description>An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.</description>
    <arm_group_label>Short course radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven locally advanced or metastatic H&amp;N cancer

          -  excluded from curative therapy because of disease stage and/or presence of multiple
             comorbidities and/or poor performance status

          -  age &gt; 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3

        Exclusion Criteria:

          -  prior RT to the same region.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessio G. Morganti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 21, 2017</last_update_submitted>
  <last_update_submitted_qc>June 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Alessio Giuseppe Morganti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>palliative care</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>pain</keyword>
  <keyword>quality of life</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

